Products for Research Use Only
RegisterLogin

Cilastatin

CAT: 0804-HY-A0166-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-A0166-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3].
CAS Number
82009-34-5
Product Name Alternative
MK0791
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Bacterial
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/Cilastatin.html
Concentration
10mM
Purity
99.91
Solubility
1M NaOH : 100 mg/mL (ultrasonic; adjust pH to 12 with NaOH) |DMSO : 100 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(O)/C(NC([C@@H]1C(C)(C)C1)=O)=C/CCCCSC[C@H](N)C(O)=O
Molecular Formula
C16H26N2O5S
Molecular Weight
358.45
Precautions
H302, H315, H319, H335
References & Citations
[1]The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterialmetallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39 (7) :1629-31.|[2]Blanca Humanes, et al. Protective Effects of Cilastatin Against Vancomycin-Induced Nephrotoxicity. Biomed Res Int. 2015;2015:704382.|[3]P J Petersen, et al. In Vitro and in Vivo Activities of LJC10,627, a New Carbapenem With Stability to Dehydropeptidase I. Antimicrob Agents Chemother. 1991 Jan;35 (1) :203-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
β-lactam

Alternative Products

CatalogName
006831-01Cilastatin
C279-100MGCilastatin Sodium
ABDIC1010AImipenem/Cilastatin

Popular Products